Dicerna sues Alnylam for alleging misappropriation of trade secrets
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) filed a suit in the U.S. District Court for the District of Massachusetts alleging that Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is using “sham litigation” to “thwart Dicerna’s competitive business activities and illegally obtain for itself market dominance” in RNAi-based treatments for primary hyperoxaluria.
In 2015, Alnylam filed a separate suit in the U.S. Superior Court for the Commonwealth of Massachusetts alleging that Dicerna unlawfully obtained and used trade secrets related to Alnylam’s GalNAc conjugate delivery technology. In 2013, Dicerna and Alnylam were in a bidding war to acquire the Sirna Therapeutics Inc. subsidiary of Merck & Co. Inc. (NYSE:MRK). Alnylam ultimately acquired Sirna and its RNAi assets and IP in 2014. The technology Alnylam gained led to the development of its GalNAc conjugate platform (see BioCentury, Jan. 20, 2014)...